Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business
ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 1, 2009-- Emergent BioSolutions Inc. (NYSE:EBS) is pleased to announce the appointment of Steven Chatfield, Ph.D. as Senior Vice President, Biodefense effective immediately. Dr. Chatfield rejoins the Company after recently serving as Executive Director of the U.K. Health Protection Agency (HPA) and leading the Agency's Centre for Emergency Preparedness and Response. In his new position, Dr. Chatfield will play a key role in the growth and development of Emergent's biodefense business, reporting directly to Daniel J. Abdun-Nabi, President and Chief Operating Officer.
"We are delighted to welcome Dr. Chatfield back to the Emergent team," said Abdun-Nabi. "A leader of Steve's stature and caliber, who brings extensive experience from both industry and government, is truly an asset in strengthening Emergent's core biodefense business not only within the U.S., but also in foreign markets, where we are expanding our presence."
With his knowledge of global biodefense issues and policies, Dr. Chatfield will be an integral part of global initiatives in government affairs, business development, and sales and marketing. He will be responsible for interacting with various government entities as well as representing the Company in scientific, investor, and business conferences related to biodefense.
"My career has been devoted to developing and implementing strategies to battle infectious diseases that have global unmet medical needs," said Dr. Chatfield. "To manage Emergent's biodefense franchise, which includes BioThrax® (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA against anthrax disease, and other product candidates that could potentially protect against deadly pathogens, gives me the opportunity to continue that mission of contributing to safeguarding the health of the world's population."
For over 27 years, Dr. Chatfield has worked in the biopharmaceutical industry and has been involved in all aspects of biopharmaceutical research and development, with a particular focus on the development of products to prevent and treat infectious disease. He is recognized internationally as an opinion leader in the area of biotechnology and has authored over 100 scientific papers in the field. Prior to joining HPA, Dr. Chatfield was Chief Scientific Officer at Emergent as well as President of Emergent Product Development U.K. from 2005 to 2007. He has also held various positions in Microscience, Medeva PLC, Evans Medical, Wellcome Biotechnology, and the Wellcome Foundation.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com and www.biothrax.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2009, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts; our plans to pursue label expansions and improvements for BioThrax®; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs, preclinical studies and clinical trials; and other factors identified in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Source: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications